Status:

COMPLETED

Lactoferrin in Helicobacter Pylori Eradication Either With Standard Triple Therapy or Sequential Therapy

Lead Sponsor:

Alexandria University

Collaborating Sponsors:

University of Alexandria

Conditions:

Helicobacter Pylori Infection

Eligibility:

All Genders

18-60 years

Phase:

PHASE4

Brief Summary

The investigators aim at evaluating the efficacy of bovine lactoferrin addition to H. Pylori eradication regimens. 400 randomly distributed participants will be assigned to one of four treatment regim...

Detailed Description

the study included 400 patients recruited from Gastroenterology as well as general internal medicine clinic at Internal Medicine department, Faculty of Medicine, University of Alexandria, Egypt. After...

Eligibility Criteria

Inclusion

  • Age group 18-60 years,
  • Positive H. Pylori test (Stool antigen / or rapid urease test)

Exclusion

  • The use of proton pump inhibitor , H2-receptor antagonist, bismuth preparation and antibiotics at least 2 weeks before enrollment,
  • prior eradication treatment,
  • History of gastrectomy,
  • Equivocal H. pylori stool antigen (HpSAg) results,
  • Severe hepatic (Child Pugh class B or C) or renal diseases (eGFR \< 60 ml/min/1.73 m\^2),
  • Any form of malignancy,
  • Proven allergy to clarithromycin, or Penicillin,
  • Pregnant or lactating females.

Key Trial Info

Start Date :

November 30 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 21 2020

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT04445948

Start Date

November 30 2019

End Date

June 21 2020

Last Update

June 25 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Faculty of Medicine

Alexandria, Egypt, 21521